BioCentury | May 10, 2018
Emerging Company Profile

Abac’s precision platform

...Funds raised: €16 million Investors: Caixa Capital Risc, Debiopharm Innovation, Global Health Sciences Venture Fund, Grupo Ferrer Internacional S.A....
BioCentury | Feb 16, 2018
Finance

Quark gets specific

...investors GF Securities Co. Ltd. (SZSE:00076; HKSE:1776), Caixa Capital Risc, Debiopharm Innovation and existing investor Grupo Ferrer Internacional S.A....
BioCentury | Feb 16, 2018
Financial News

Abac raises €16M series A

...Health Science Fund, Caixa Capital Risc and Debiopharm Innovation Fund participated, as did existing investor Ferrer...
...Pontifax's Silvia Noiman, Quark Venture's Zafrira Avnur, Caixa's Carlos Esteban, Debiopharm's Bea Arnold and Ferrer's...
BioCentury | Feb 15, 2018
Financial News

Pontifax leads Abac’s €16M series A round

...Health Science Fund, Caixa Capital Risc and Debiopharm Innovation Fund participated, as did existing investor Ferrer...
...Pontifax's Silvia Noiman, Quark Venture's Zafrira Avnur, Caixa's Carlos Esteban, Debiopharm's Bea Arnold and Ferrer's...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Dec 28, 2017
Company News

Management tracks: Vivus, Peregrine

...replacement. King was president and CEO of Alexza Pharmaceuticals Inc. until its 2016 acquisition by Grupo Ferrer Internacional S.A....
BioCentury | Sep 29, 2017
Financial News

Engage, Integra raise venture financings

...1Q18. Engage has rights to the candidate from Alexza Pharmaceuticals Inc. , a subsidiary of Grupo Ferrer Internacional S.A....
...Engage Therapeutics Inc. , Summit, N.J. Integra Holdings, Jerusalem, Israel Jennie Walters Staccato alprazolam Alexza Pharmaceuticals Inc. Avraham Pharmaceuticals Ltd. Grupo Ferrer Internacional S.A. Hebrew...
BioCentury | Sep 28, 2017
Financial News

Venture roundup: Engage, Integra

...1Q18. Engage has rights to the candidate from Alexza Pharmaceuticals Inc. , a subsidiary of Grupo Ferrer Internacional S.A....
...The firm's portfolio includes Alzheimer's disease company Avraham Pharmaceuticals Ltd. (Yavneh, Israel). Jennie Walters Staccato alprazolam Alexza Pharmaceuticals Inc. Grupo Ferrer Internacional S.A. Engage...
BioCentury | May 19, 2017
Clinical News

Lorediplon meets in Phase II insomnia trial

...measurements, next-day residual effects and pharmacokinetics. Lorediplon is a long-acting non-benzodiazapine GABA A receptor modulator. Grupo Ferrer Internacional S.A....
...in collaboration with CRO Ergomed and Ildong Pharmaceutical Co. Ltd. (KSE:000230). Ildong has rights from Ferrer...
...Korea, China and Japan (see BioCentury, Feb. 10, 2014 ). Ergomed plc (LSE:ERGO), Guilford, U.K. Grupo Ferrer Internacional S.A....
BioCentury | Oct 13, 2016
Distillery Therapeutics

Therapeutics: Monocyte chemoattractant protein-1 (MCP-1; CCL2)

...del Toro, R. et al. Nat. Comm.; published online Sept. 2, 2016 doi:10.1038/ncomms12706 CONTACT: Simón Médez-Ferrer...
Items per page:
1 - 10 of 132
BioCentury | May 10, 2018
Emerging Company Profile

Abac’s precision platform

...Funds raised: €16 million Investors: Caixa Capital Risc, Debiopharm Innovation, Global Health Sciences Venture Fund, Grupo Ferrer Internacional S.A....
BioCentury | Feb 16, 2018
Finance

Quark gets specific

...investors GF Securities Co. Ltd. (SZSE:00076; HKSE:1776), Caixa Capital Risc, Debiopharm Innovation and existing investor Grupo Ferrer Internacional S.A....
BioCentury | Feb 16, 2018
Financial News

Abac raises €16M series A

...Health Science Fund, Caixa Capital Risc and Debiopharm Innovation Fund participated, as did existing investor Ferrer...
...Pontifax's Silvia Noiman, Quark Venture's Zafrira Avnur, Caixa's Carlos Esteban, Debiopharm's Bea Arnold and Ferrer's...
BioCentury | Feb 15, 2018
Financial News

Pontifax leads Abac’s €16M series A round

...Health Science Fund, Caixa Capital Risc and Debiopharm Innovation Fund participated, as did existing investor Ferrer...
...Pontifax's Silvia Noiman, Quark Venture's Zafrira Avnur, Caixa's Carlos Esteban, Debiopharm's Bea Arnold and Ferrer's...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Dec 28, 2017
Company News

Management tracks: Vivus, Peregrine

...replacement. King was president and CEO of Alexza Pharmaceuticals Inc. until its 2016 acquisition by Grupo Ferrer Internacional S.A....
BioCentury | Sep 29, 2017
Financial News

Engage, Integra raise venture financings

...1Q18. Engage has rights to the candidate from Alexza Pharmaceuticals Inc. , a subsidiary of Grupo Ferrer Internacional S.A....
...Engage Therapeutics Inc. , Summit, N.J. Integra Holdings, Jerusalem, Israel Jennie Walters Staccato alprazolam Alexza Pharmaceuticals Inc. Avraham Pharmaceuticals Ltd. Grupo Ferrer Internacional S.A. Hebrew...
BioCentury | Sep 28, 2017
Financial News

Venture roundup: Engage, Integra

...1Q18. Engage has rights to the candidate from Alexza Pharmaceuticals Inc. , a subsidiary of Grupo Ferrer Internacional S.A....
...The firm's portfolio includes Alzheimer's disease company Avraham Pharmaceuticals Ltd. (Yavneh, Israel). Jennie Walters Staccato alprazolam Alexza Pharmaceuticals Inc. Grupo Ferrer Internacional S.A. Engage...
BioCentury | May 19, 2017
Clinical News

Lorediplon meets in Phase II insomnia trial

...measurements, next-day residual effects and pharmacokinetics. Lorediplon is a long-acting non-benzodiazapine GABA A receptor modulator. Grupo Ferrer Internacional S.A....
...in collaboration with CRO Ergomed and Ildong Pharmaceutical Co. Ltd. (KSE:000230). Ildong has rights from Ferrer...
...Korea, China and Japan (see BioCentury, Feb. 10, 2014 ). Ergomed plc (LSE:ERGO), Guilford, U.K. Grupo Ferrer Internacional S.A....
BioCentury | Oct 13, 2016
Distillery Therapeutics

Therapeutics: Monocyte chemoattractant protein-1 (MCP-1; CCL2)

...del Toro, R. et al. Nat. Comm.; published online Sept. 2, 2016 doi:10.1038/ncomms12706 CONTACT: Simón Médez-Ferrer...
Items per page:
1 - 10 of 132